

Ezabenlimab Biosimilar - Research Grade

Product Code: ICH5238

More Information

Species Reactivity: Human

Target: PD-1

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Ezabenlimab Biosimilar - Research Grade

Antibodies against the same target: [Anti-Mouse PD-1 \(29F.1A12\) In Vivo Antibody - Low Endotoxin \(ICH1091\)](#), [Anti-PD-1 \(RMP1-14\) \(ICH1132\)](#), [Anti-Mouse PD-1 \(RMP1-14\) Recombinant Antibody \(ICH1182\)](#), [Mouse Anti-Mouse PD-1 \(29F.1A12\) Recombinant Antibody \(ICH1211\)](#), [Anti-Mouse PD-1 \(RMP1-30\) In Vivo Antibody - Low Endotoxin \(ICH1246\)](#), [Anti-Human PD-1 \(J110\) In Vivo Antibody - Low Endotoxin \(ICH1272\)](#), [Nivolumab Biosimilar - Research Grade \(ICH4009\)](#), [Pembrolizumab Biosimilar - Research Grade \(ICH4029\)](#), [Sintilimab Biosimilar - Research Grade \(ICH5001\)](#), [Toripalimab Biosimilar - Research Grade \(ICH5002\)](#), [Camrelizumab Biosimilar - Research Grade \(ICH5003\)](#), [Tislelizumab Biosimilar - Research Grade \(ICH5004\)](#), [Penpulimab Biosimilar - Research Grade \(ICH5112\)](#), [Cemiplimab Biosimilar - Research Grade \(ICH5161\)](#), [Peresolimab Biosimilar - Research Grade \(ICH5221\)](#), [Acrixolimab Biosimilar - Research Grade \(ICH5224\)](#), [Adebrelimab Biosimilar - Research Grade \(ICH5225\)](#), [Enlonstobart Biosimilar - Research Grade \(ICH5234\)](#), [Finotonlimab Biosimilar - Research Grade \(ICH5241\)](#), [Geptanolimab Biosimilar - Research Grade \(ICH5243\)](#), [Iparomlimab Biosimilar - Research Grade \(ICH5248\)](#), [Lipustobart Biosimilar - Research Grade \(ICH5254\)](#), [Nofazinlimab Biosimilar - Research Grade \(ICH5262\)](#), [Pimivalimab Biosimilar - Research Grade \(ICH5266\)](#), [Pradusinstobart Biosimilar - Research Grade \(ICH5268\)](#), [Pucotenlimab Biosimilar - Research Grade \(ICH5269\)](#), [Sugemalimab Biosimilar - Research Grade \(ICH5278\)](#), [Zimberelimab Biosimilar - Research Grade \(ICH5292\)](#), [Retifanlimab Biosimilar - Research Grade \(ICH5296\)](#), [Dostarlimab Biosimilar - Research Grade \(ICH5311\)](#), [Balstilimab Biosimilar - Research Grade \(ICH5369\)](#),

[Budigalimab Biosimilar - Research Grade \(ICH5417\)](#), [Cetrelimab Biosimilar - Research Grade \(ICH5434\)](#), [Gilvetmab Biosimilar - Research Grade \(ICH5572\)](#), [Lodapolimab Biosimilar - Research Grade \(ICH5651\)](#), [Pidilizumab Biosimilar - Research Grade \(ICH5773\)](#), [Prolgolimab Biosimilar - Research Grade \(ICH5791\)](#), [Rosnilimab Biosimilar - Research Grade \(ICH5837\)](#), [Rulonilimab Biosimilar - Research Grade \(ICH5840\)](#), [Sasanlimab Biosimilar - Research Grade \(ICH5848\)](#), [Serplulimab Biosimilar - Research Grade \(ICH5855\)](#), [Spartalizumab Biosimilar - Research Grade \(ICH5881\)](#), [Zeluvalimab Biosimilar - Research Grade \(ICH6006\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q15116

Shipping Conditions: Blue ice

background: This product is an unconjugated, non-therapeutic recombinant analog of the anti-PD-1 antibody ezabenlimab, supplied for research use only. It reproduces a human IgG4-kappa format directed against human PD-1 (PDCD1, UniProt Q15116) and is intended to block the PD-1/PD-L1 and PD-1/PD-L2 interaction in laboratory settings. It is not the clinical drug and is not for human or veterinary use. The recombinant format makes it useful as a defined, lot-consistent reagent for PD-1 checkpoint research: as a positive control or benchmarking tool in PD-1/PD-L1 blockade assays, as a capture or detection reagent in binding and epitope studies, and as a comparator in biosimilarity or ADCC/ADC-development workflows. Because it is offered unconjugated, users can label or immobilise it for their own assay formats. It is manufactured to low-endotoxin research grade (typically under 1 EU/mg, with an ultra-low under 0.5 EU/mg option) and is available in bulk milligram-to-gram quantities to support screening campaigns, preclinical model work, and reagent standardisation across experiments. Guidance provided for ichorbio to review. PD-1 (programmed cell death protein 1; gene PDCD1, UniProt Q15116) is a type I transmembrane immune checkpoint receptor of the CD28/immunoglobulin superfamily, expressed on activated T cells and, to varying degrees, on B cells, NK cells, and myeloid subsets. Its cytoplasmic tail carries ITIM and ITSM motifs that, upon ligand engagement, recruit the phosphatase SHP-2 to dampen TCR and CD28 signalling, promoting T-cell exhaustion and peripheral tolerance. PD-1 has two ligands, PD-L1 (CD274) and PD-L2 (CD273), which are frequently upregulated in the tumour microenvironment, allowing tumours to evade immune attack. Antibodies that block PD-1 from binding PD-L1/PD-L2 relieve this inhibitory signal and restore effector T-cell activity, the mechanistic basis of PD-

1 checkpoint blockade in immuno-oncology research.

Other names: Protein PD-1, hPD-1, Programmed cell death protein 1, PDCD1

Specificity: Detects human PD-1

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks